Advances in the effect of inhibiting complement activation in the treatment of sepsis-associated coagulopathy.
10.3760/cma.j.cn121430-20220822-00768
- Author:
Xin LU
1
;
Xin WEI
2
;
Zhibin WANG
1
Author Information
1. Department of Critical Care Medicine, School of Anesthesiology, Naval Medical University, Shanghai 200433, China.
2. Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China. Corresponding author: Wang Zhibin, Email: methyl@smmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Blood Coagulation Disorders;
Complement Activation;
Blood Coagulation;
Multiple Organ Failure;
Sepsis
- From:
Chinese Critical Care Medicine
2023;35(4):438-441
- CountryChina
- Language:Chinese
-
Abstract:
Sepsis-associated coagulopathy refers to extensive coagulation activation accompanied by a high risk of bleeding and organ failure. In severe cases, it is manifested as disseminated intravascular coagulation (DIC) and leads to multiple organ dysfunction syndrome (MODS). Complement is an important component of the innate immune system and plays an important role in defending against invasion of pathogenic microorganisms. The early pathological process of sepsis involves excessive activation of the complement system, which forms an extremely complex network through interactions with the coagulation, kinin and fibrinolytic system, amplifying and exacerbating the systemic inflammatory response. In recent years, it has been suggested that uncontrolled complement activation system can exacerbate sepsis-associated coagulation dysfunction or even DIC, indicating the potential value of intervening in the complement system in the treatment of septic DIC, and related research progress is reviewed in this article in order to provide new ideas for the discovery of sepsis-associated coagulopathy therapy drugs.
